A recap of the day s headlines and a look at what s in store for tomorrow.
dealing in u.s. dollars, currency abroad, business and precious metals, aluminum, steel and coal. and that s only phase one. in less than three months the administration hits iran s oil production and banking sector. shannon: thank you very much. those new sanctions kick in against iran at 12 oh one eastern time. lindsey graham, member of the senate armed services committee joins us now to dig in further. the sanctions kick in and iran is complain about it, senator. strong message is not just for them but also for our allies. the united states is fully committed to enforcing all of our sanctions and we will work closely with nations conducting business with iran to ensure complete complaints. individuals or entities that fail to wind down activities with our brand with severe consequences. who is that for? that s for anyone, particularly the iranians that prop up the ayatollah. they ve made the decision t
Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.
Experts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.
Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.